• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿比特龙及其在转移性 CRPC 治疗中的地位。

Abiraterone and its place in the treatment of metastatic CRPC.

机构信息

Department of Medicine, Tulane Medical School, Box SL-42, 1430 Tulane Avenue, New Orleans, LA 70112, USA.

出版信息

Nat Rev Clin Oncol. 2013 Jan;10(1):6-8. doi: 10.1038/nrclinonc.2012.202. Epub 2012 Nov 13.

DOI:10.1038/nrclinonc.2012.202
PMID:23149889
Abstract

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.

摘要

COU-AA-301 研究的更新结果证实，与多西他赛化疗后给予泼尼松相比，阿比特龙联合泼尼松可使转移性去势抵抗性前列腺癌患者的生存获益。我们将这些数据与之前的疾病状态和其他新型药物进行了对比，并探讨了与阿比特龙未来应用相关的实际问题。

相似文献

1
Abiraterone and its place in the treatment of metastatic CRPC.阿比特龙及其在转移性 CRPC 治疗中的地位。
Nat Rev Clin Oncol. 2013 Jan;10(1):6-8. doi: 10.1038/nrclinonc.2012.202. Epub 2012 Nov 13.
2
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
3
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.欧洲药品管理局对阿比特龙用于多西他赛化疗后成年男性转移性去势抵抗性前列腺癌以及初治疾病的审查：人用药品委员会科学评估摘要
Oncologist. 2013;18(9):1032-42. doi: 10.1634/theoncologist.2013-0092. Epub 2013 Aug 21.
4
New treatment options for patients with metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌患者的新治疗选择。
Cancer Treat Rev. 2012 Aug;38(5):340-5. doi: 10.1016/j.ctrv.2011.07.007. Epub 2011 Sep 23.
5
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.醋酸阿比特龙联合泼尼松治疗多西他赛治疗失败的去势抵抗性前列腺癌的多中心 II 期研究。
J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.
6
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.阿比特龙联合泼尼松可改善转移性去势抵抗性前列腺癌患者的生存率。
Asian J Androl. 2011 Nov;13(6):785-6. doi: 10.1038/aja.2011.113. Epub 2011 Aug 22.
7
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.在后多西他赛治疗环境下转移性前列腺癌的新型治疗策略。
Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2.
8
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].阿比特龙和卡巴他赛的同情用药：多西他赛预处理的去势抵抗性前列腺癌患者的首次经验
Urologe A. 2012 Mar;51(3):390-7. doi: 10.1007/s00120-012-2804-y.
9
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.阿比特龙和己烯雌酚序贯给药治疗去势抵抗性前列腺癌的抗肿瘤活性。
Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8.
10
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.英国国家卫生与临床优化研究所（NICE）关于阿比特龙用于先前接受含多西他赛方案治疗的去势抵抗性转移性前列腺癌的指南。
Lancet Oncol. 2012 Aug;13(8):762-3. doi: 10.1016/s1470-2045(12)70289-9.

引用本文的文献

1
Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.Sprouty2 缺失诱导的 IL6 通过清道夫受体 B1 驱动去势抵抗性前列腺癌。
EMBO Mol Med. 2018 Apr;10(4). doi: 10.15252/emmm.201708347.
2
Involvement of Bax and Bcl-2 in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells.三种黎巴嫩鼠尾草属植物精油通过 Bax 和 Bcl-2 诱导人前列腺癌细胞凋亡。
Int J Mol Sci. 2018 Jan 19;19(1):292. doi: 10.3390/ijms19010292.
3
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation.

本文引用的文献

1
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.转移性去势抵抗性前列腺癌中多西他赛治疗失败的管理。
Urol Clin North Am. 2012 Nov;39(4):583-91. doi: 10.1016/j.ucl.2012.07.013. Epub 2012 Aug 29.
2
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙治疗转移性去势抵抗性前列腺癌：COU-AA-301 随机、双盲、安慰剂对照 3 期研究的最终总生存分析。
Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18.
3
UAP1 在前列腺癌中过表达，并对 N-连接糖基化抑制剂具有保护作用。
Oncogene. 2015 Jul;34(28):3744-50. doi: 10.1038/onc.2014.307. Epub 2014 Sep 22.
4
Pomegranate and its components as alternative treatment for prostate cancer.石榴及其成分作为前列腺癌的替代治疗方法。
Int J Mol Sci. 2014 Aug 25;15(9):14949-66. doi: 10.3390/ijms150914949.
5
Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.木犀草素、鞣花酸和石榴酸是抑制前列腺癌转移的天然产物。
Carcinogenesis. 2014 Oct;35(10):2321-30. doi: 10.1093/carcin/bgu145. Epub 2014 Jul 14.
6
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.雄激素剥夺在前列腺癌中快速诱导雄激素受体剪接变体
Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
恩杂鲁胺可提高化疗后前列腺癌患者的生存率。
N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
4
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?多西他赛治疗后 CYP17A1 抑制剂阿比特龙的抗肿瘤活性：交叉耐药的临床证据？
Ann Oncol. 2012 Nov;23(11):2943-2947. doi: 10.1093/annonc/mds119. Epub 2012 Jul 5.
5
Duration of androgen suppression in the treatment of prostate cancer.雄激素抑制在前列腺癌治疗中的持续时间。
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
6
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.醋酸阿比特龙对CYP17的选择性抑制在去势抵抗性前列腺癌的治疗中具有高度活性。
J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.
7
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.进展性前列腺癌和睾酮去势水平患者的临床试验设计与终点：前列腺癌临床试验工作组的建议
J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.